|
1
|
Piazuelo MB and Correa P: Gastric cáncer:
Overview. Colomb Med (Cali). 44:192–201. 2013.PubMed/NCBI
|
|
2
|
Wagner AD, Unverzagt S, Grothe W, Kleber
G, Grothey A, Haerting J and Fleig WE: Chemotherapy for advanced
gastric cancer. Cochrane Database Syst Rev. CD004064:2010.
View Article : Google Scholar
|
|
3
|
Van Cutsem E, Haller D and Ohtsu A: The
role of chemotherapy in the current treatment of gastric cancer.
Gastric Cancer. 5:(Suppl 1). 17–22. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gura T: How TRAIL kills cancer cells, but
not normal cells. Science. 277:7681997. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Baker SJ and Reddy EP: Modulation of life
and death by the TNF receptor superfamily. Oncogene. 17:3261–3270.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ashkenazi A: Targeting death and decoy
receptors of the tumour-necrosis factor superfamily. Nat Rev
Cancer. 2:420–430. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Srivastava RK: TRAIL/Apo-2L: Mechanisms
and clinical applications in cancer. Neoplasia. 3:535–546. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Prasad S, Yadav VR, Kannappan R and
Aggarwal BB: Ursolic acid, a pentacyclin triterpene, potentiates
TRAIL-induced apoptosis through p53-independent up-regulation of
death receptors: Evidence for the role of reactive oxygen species
and JNK. J Biol Chem. 286:5546–5557. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Siddiqui IA, Malik A, Adhami VM, Asim M,
Hafeez BB, Sarfaraz S and Mukhtar H: Green tea polyphenol EGCG
sensitizes human prostate carcinoma LNCaP cells to TRAIL-mediated
apoptosis and synergistically inhibits biomarkers associated with
angiogenesis and metastasis. Oncogene. 27:2055–2063. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Szliszka E and Krol W: The role of dietary
polyphenols in tumor necrosis factor-related apoptosis inducing
ligand (TRAIL)-induced apoptosis for cancer chemoprevention. Eur J
Cancer Prev. 20:63–69. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xia YF, Ye BQ, Li YD, Wang JG, He XJ, Lin
X, Yao X, Ma D, Slungaard A, Hebbel RP, et al: Andrographolide
attenuates inflammation by inhibition of NF-kappa B activation
through covalent modification of reduced cysteine 62 of p50. J
Immunol. 173:4207–4217. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang YJ, Wang JT, Fan QX and Geng JG:
Andrographolide inhibits NF-kappaBeta activation and attenuates
neointimal hyperplasia in arterial restenosis. Cell Res.
17:933–941. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang QQ, Zhou DL, Ding Y, Liu HY, Lei Y,
Fang HY, Gu QL, He XD, Qi CL, Yang Y, et al: Andrographolide
inhibits melanoma tumor growth by inactivating the TLR4/NF-κB
signaling pathway. Melanoma Res. 24:545–555. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang QQ, Ding Y, Lei Y, Qi CL, He XD, Lan
T, Li JC, Gong P, Yang X, Geng JG and Wang LJ: Andrographolide
suppress tumor growth by inhibiting TLR4/NF-κB signaling activation
in insulinoma. Int J Biol Sci. 10:404–414. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu SH, Lin CH, Liang FP, Chen PF, Kuo CD,
Alam MM, Maiti B, Hung SK, Chi CW, Sun CM and Fu SL:
Andrographolide downregulates the v-Src and Bcr-Abl oncoproteins
and induces Hsp90 cleavage in the ROS-dependent suppression of
cancer malignancy. Biochem Pharmacol. 87:229–242. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shen K, Ji L, Lu B, Xu C, Gong C, Morahan
G and Wang Z: Andrographolide inhibits tumor angiogenesis via
blocking VEGFA/VEGFR2-MAPKs signaling cascade. Chem Biol Interact.
218:99–106. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang SH, Wang SM, Syu JP, Chen Y, Wang SD,
Peng YS, Kuo MF and Kung HN: Andrographolide induces apoptosis of
C6 glioma cells via the ERK-p53-caspase 7-PARP pathway. Biomed Res
Int. 2014:3128472014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li J, Zhang C, Jiang H and Cheng J:
Andrographolide inhibits hypoxia-inducible factor-1 through
phosphatidylinositol 3-kinase/AKT pathway and suppresses breast
cancer growth. Onco Targets Ther. 8:427–435. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nateewattana J, Dutta S, Reabroi S, Saeeng
R, Kasemsook S, Chairoungdua A, Weerachayaphorn J, Wongkham S and
Piyachaturawat P: Induction of apoptosis in cholangiocarcinoma by
an andrographolide analogue is mediated through topoisomerase II
alpha inhibition. Eur J Pharmacol. 723:148–155. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lu CY, Yang YC, Li CC, Liu KL, Lii CK and
Chen HW: Andrographolide inhibits TNFα-induced ICAM-1 expression
via suppression of NADPH oxidase activation and induction of HO-1
and GCLM expression through the PI3K/Akt/Nrf2 and PI3K/Akt/AP-1
pathways in human endothelial cells. Biochem Pharmacol. 91:40–50.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhou J, Ong CN, Hur GM and Shen HM:
Inhibition of the JAK-STAT3 pathway by andrographolide enhances
chemosensitivity of cancer cells to doxorubicin. Biochem Pharmacol.
79:1242–1250. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lin HH, Shi MD, Tseng HC and Chen JH:
Andrographolide sensitizes the cytotoxicity of human colorectal
carcinoma cells toward cisplatin via enhancing apoptosis pathways
in vitro and in vivo. Toxicol Sci. 139:108–120. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shin JN, Park SY, Cha JH, Park JY, Lee BR,
Jung SA, Lee ST, Yun CW, Seol DW and Kim TH: Generation of a novel
proform of tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL) protein that can be reactivated by matrix
metalloproteinases. Exp Cell Res. 312:3892–3898. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Laemmli UK: Cleavage of structural
proteins during the assembly of the head of bacteriophage T4.
Nature. 227:680–685. 1970. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Franken NA, Rodermond HM, Stap J, Haveman
J and van Bree C: Clonogenic assay of cells in vitro. Nat Protoc.
1:2315–2319. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rafehi H, Orlowski C, Georgiadis GT,
Ververis K, El-Osta A and Karagiannis TC: Clonogenic assay:
Adherent cells. J Vis Exp. pii: 2573. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
el-Deiry WS, Harper JW, O'Connor PM,
Velculescu VE, Canman CE, Jackman J, Pietenpol JA, Burrell M, Hill
DE, Wang Y, et al: WAF1/CIP1 is induced in p53-mediated G1 arrest
and apoptosis. Cancer Res. 54:1169–1174. 1994.PubMed/NCBI
|
|
28
|
Wu GS, Burns TF, McDonald ER III, Jiang W,
Meng R, Krantz ID, Kao G, Gan DD, Zhou JY, Muschel R, et al:
KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor
gene. Nat Genet. 17:141–143. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sheikh MS, Burns TF, Huang Y, Wu GS,
Amundson S, Brooks KS, Fornace AJ Jr and el-Deiry WS: p53-dependent
and -independent regulation of the death receptor KILLER/DR5 gene
expression in response to genotoxic stress and tumor necrosis
factor alpha. Cancer Res. 58:1593–1598. 1998.PubMed/NCBI
|
|
30
|
Park JG, Yang HK, Kim WH, Chung JK, Kang
MS, Lee JH, Oh JH, Park HS, Yeo KS, Kang SH, et al: Establishment
and characterization of human gastric carcinoma cell lines. Int J
Cancer. 70:443–449. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ruiz-González R, Milán P, Bresolí-Obach R,
Stockert JC, Villanueva A, Cañete M and Nonell S: Photodynamic
Synergistic Effect of Pheophorbide a and Doxorubicin in Combined
Treatment against Tumoral Cells. Cancers (Basel). 9:pii: E18. 2017.
View Article : Google Scholar
|
|
32
|
Jerzak KJ, Berry S, Ko YJ, Earle C and
Chan KK: Cetuximab plus Irinotecan versus Panitumumab in Patients
with refractory metastatic colorectal cancer in Ontario, Canada.
Int J Cancer. 2017.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang W and Tung CH: Cisplatin
Cross-linked Multifunctional Nanodrugplexes for Combination
Therapy. ACS Appl Mater Interfaces. 2017.(Epub ahead of print).
|
|
34
|
Zhang H, Dong L, Chen Q, Kong L, Meng B,
Wang H, Fu K and Wang X, Pan-Hammarström Q, Wang P and Wang X:
Synergistic antitumor effect of histone deacetylase inhibitor and
Doxorubicin in peripheral T-cell lymphoma. Leuk Res. 56:29–35.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jung EM, Lim JH, Lee TJ, Park JW, Choi KS
and Kwon TK: Curcumin sensitizes tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL)-induced apoptosis through
reactive oxygen species-mediated upregulation of death receptor 5
(DR5). Carcinogenesis. 26:1905–1913. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tang SY, Zhong MZ, Yuan GJ, Hou SP, Yin
LL, Jiang H and Yu Z: Casticin, a flavonoid, potentiates
TRAIL-induced apoptosis through modulation of anti-apoptotic
proteins and death receptor 5 in colon cancer cells. Oncol Rep.
29:474–480. 2013.PubMed/NCBI
|
|
37
|
Zhou Y, Tian L, Long L, Quan M, Liu F and
Cao J: Casticin potentiates TRAIL-induced apoptosis of gastric
cancer cells through endoplasmic reticulum stress. PLoS One.
8:e588552013. View Article : Google Scholar : PubMed/NCBI
|
